程序性死亡配体1检查点抑制后CD8+与FoxP3+T细胞密度及空间分布变化
本研究分析durvalumab联合或不联合二甲双胍新辅助治疗头颈部鳞状细胞癌(HNSCC)样本中CD8+与FoxP3+T细胞密度及细胞间距离。治疗后联合二甲双胍组肿瘤邻近间质FoxP3+密度显著降低、CD8+密度升高,两治疗组细胞间距离均显著增加。细胞间距离增大与病理缓解相关,T细胞分布可能预测免疫检查点抑制的疗效。
要点
- 联合二甲双胍组治疗后肿瘤邻近间质FoxP3+密度降低、CD8+密度升高。
- 两治疗组治疗后CD8+-FoxP3+细胞间距离均显著增加。
- 基线CD8+密度和细胞间距离较大的患者病理缓解率更高。
核心结论
- CD8+与FoxP3+T细胞分布差异与HPV状态、病理缓解及治疗相关,较大的CD8+-FoxP3+细胞间距离与病理缓解相关。
研究设计与样本
- 分析durvalumab联合或不联合二甲双胍新辅助治疗试验中头颈部鳞状细胞癌(HNSCC)配对治疗前后原发肿瘤样本的CD8+与FoxP3+T细胞密度及细胞间距离。
主要发现
- 治疗后分析显示,与单用durvalumab相比,durvalumab联合二甲双胍组患者肿瘤邻近间质(TAS)中FoxP3+细胞密度显著降低、CD8+细胞密度升高。
- 两个治疗组治疗后细胞间距离均显著增加。
- HPV+与HPV-样本在肿瘤微环境中免疫细胞密度相似,但HPV+治疗前样本的细胞间距离为HPV-样本的1.60倍,趋势接近统计学显著(p=0.05)。
- 基线时病理缓解者肿瘤前缘(LTE)CD8+细胞密度为非缓解者的1.16倍(p=0.045),细胞间距离为非缓解者的2.28倍(p=0.001)。
- 数字空间分析显示病理缓解者肿瘤邻近间质中FoxP3+和细胞毒性T淋巴细胞相关抗原4(CTLA-4)表达上调(p=0.006,p=0.026)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To analyze CD8+ and FoxP3+ T-cell cellular density (CD) and intercellular distances (ID) in head and neck squamous cell carcinoma (HNSCC) samples from a neoadjuvant trial of durvalumab +/- metformin. METHODS: Paired pre- and post-treatment primary HNSCC tumor samples were stained for CD8+ and FoxP3+. Digital image analysis was used to determine estimated mean CD8+ and FoxP3+ CDs and CD8+-FoxP3+ IDs in the leading tumor edge (LTE) and tumor adjacent stroma (TAS) stratified by treatment arm, human papillomavirus (HPV) status, and pathologic treatment response. A subset of samples was characterized for T-cell related signatures using digital spatial genomic profiling. RESULTS: Post-treatment analysis revealed a significant decrease in FoxP3+ CD and an increase in CD8+ CDs in the TAS between patients receiving durvalumab and metformin versus durvlaumab alone. Both treatment arms demonstrated significant post-treatment increases in ID. Although HPV+ and HPV- had similar immune cell CDs in the tumor microenvironment, HPV+ pre-treatment samples had 1.60 times greater ID compared with HPV- samples, trending toward significance (p = 0.05). At baseline, pathologic responders demonstrated a 1.16-fold greater CD8+ CDs in the LTE (p = 0.045) and 2.28-fold greater ID (p = 0.001) than non-responders. Digital spatial profiling revealed upregulation of FoxP3+ and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) in the TAS (p = 0.006, p = 0.026) in samples from pathologic responders. CONCLUSIONS: Analysis of CD8+ and FoxP3+ detected population differences according to HPV status, pathologic response, and treatment. Greater CD8+-FoxP3+ ID was associated with pathologic response. CD8+ and FoxP3+ T-cell distributions may be predictive of response to immune checkpoint inhibition. CLINICALTRIALS: gov (Identifier NCT03618654). LEVEL OF EVIDENCE: 3 Laryngoscope, 133:1875-1884, 2023.
引用
- Curry J, Alnemri A, Philips R, et al. CD8+ and FoxP3+ T-Cell Cellular Density and Spatial Distribution After Programmed Death-Ligand 1 Check Point Inhibition. Laryngoscope. 2022. PMID: 36125263. doi:10.1002/lary.30389
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。